DaVita Inc. Q4 Sales Increase

DaVita reported Q4 revenue of $3.61 billion, up 9.7% year-over-year, with GAAP net income of $234.21 million (EPS $3.29) versus $259.32 million (EPS $3.09) in the prior year; adjusted EPS was $3.40. Management provided full-year guidance of $13.60 to $15.00, indicating solid top-line growth alongside mixed headline profitability that warrants attention to margin drivers and guidance execution.

Analysis

Market structure: DaVita’s 9.7% revenue growth and $3.40 adjusted EPS signal durable demand for dialysis services and continued share-holder-friendly capital allocation (buybacks implied by lower GAAP profits but higher EPS). Direct winners are DVA equity holders and short-term bondholders if credit spreads tighten; payors (Medicare/private insurers) are marginally pressured but not immediately disrupted. Cross-asset: expect modest compression in DVA credit spreads (tightening by 25–75bp possible) and a small decline in implied equity volatility; FX and commodities immaterial.

Risk assessment: Key tail risks are regulatory (CMS reimbursement rule changes that cut payments >3–5%), large litigation/settlement (> $200M) or severe staffing-driven margin erosion (EBITDA margin fall >200bp). Immediate (days) risk is post-print price chop; short-term (weeks/months) revolves around guidance clarity and CMS proposals; long-term (quarters/years) centers on reimbursement trajectory and capex for home dialysis. Catalysts: next CMS rule window (90–180 days), Q1 call, and any announced M&A or buyback increments.

Trade implications: Favor directional exposure to DVA with defined risk: establish a 2–3% long equity position sized to portfolio volatility, and allocate 0.8–1.2% to a 6–9 month DVA call spread (buy OTM call / sell further OTM) to lever upside to the $13.60–$15.00 guide. Pair trade: long DVA vs short FMS (FMS) in a 1:0.9 dollar-neutral ratio to capture idiosyncratic outperformance if U.S. incumbents execute better. Consider buying 6–12 month protective puts if CMS proposal signal appears (cost <1% of portfolio) and trim on +15% outperformance.

Contrarian angles: The market may under-appreciate that buybacks are propping EPS while GAAP net fell (profits down from $259M to $234M), creating downside if buybacks pause. Consensus is mildly positive but underestimates regulatory stickiness; if CMS maintains status quo, DVA upside is underpriced — expect a 12–25% re-rating over 6–12 months. Conversely, an adverse CMS move could trigger a >20% drawdown; asymmetric outcomes justify defined-risk options rather than naked exposure.

Key Decisions for Investors

• Establish a 2–3% long position in DVA equity within 1–2 weeks, scale in, and add up to another 1% on any pullback of ≥10% from today’s level; target holding period 6–12 months, trim if DVA rallies +15%.
• Allocate 0.8–1.2% of portfolio to a 6–9 month DVA call spread (buy near-ATM call, sell 15–25% OTM call) to capture upside toward the $13.60–$15.00 guidance range while capping premium outlay.
• Implement a pair trade: long DVA 2% vs short FMS 1.8% (dollar-neutral) for 3–9 months to exploit U.S. incumbents’ operational leverage; exit if spread compresses by >50% or DVA underperforms by 10% absolute.
• Set hard risk rules: buy 6–12 month protective puts (cost budgeted ≤1% of portfolio) if CMS publishes a draft reimbursement reduction ≥3% or if DVA reissues buyback guidance pause; stop-loss on equity leg at -12% absolute within 4 weeks of entry.